SIEN
SIENTRA INC (SIEN)
$1.93
Market is closedMarket is closed – opens on 8 PM, 06 Feb 2023
– opens on 8 PM, 06 Feb 2023
Key Stats
$1.83
Day's Range
$2.07
$1.49
52-Week Range
$33.8
| Returns % | |
| 1 month return | 14.83% |
| 3 month return | 7.22% |
| 1 year return | 29.56% |
| 5 year return | 82.94% |
Analyst Recommendation
based on 11 analysts ratings
Buy
81%
Buy
18%
Hold
0%
Sell
Based on 11 Wall street analysts offering stock ratings for SIENTRA INC(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 772.02%Current
$1.93
Target
$16.83
Recommendation Trend
Based on 11 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 9 | 8 | 11 |
| Hold | 2 | 0 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 19.7M |
| Book Value | - $0.69 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -0.44 |
| PEG Ratio | -0.27 |
| Wall Street Target Price | 16.83 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 13.09 |
| Enterprise Value | 87.1M |
| Enterprise Value/Revenue | 0.99 |
| Enterprise Value/Ebitda | -1.67 |
Technicals
| Beta | 1.59 |
| 50 Day MA | 2.33 |
| 200 Day MA | 6.91 |
Institutional Holdings
Morgan Stanley - Brokerage Accounts
33.6%
Vanguard Group Inc
27.9%
Blackstone Inc
27.04%
BAMCO Inc
25.53%
Needham Investment Management, LLC
22.97%
Abingworth LLP
16.57%
Company Information
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company uniquely focused on plastic surgeons. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company's Breast Products Segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company's miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.
| Organization | SIENTRA INC |
| Employees | 319 |
| CEO | Mr. Ronald Menezes |
| Industry | Health Technology |
Discover more
Frequently Asked Questions
What is SIENTRA INC share price today?
Can Indians buy SIENTRA INC shares?
How can I buy SIENTRA INC shares from India?
Can Fractional shares of SIENTRA INC be purchased?
What are the documents required to start investing in SIENTRA INC stocks?
What are today’s High and Low prices of SIENTRA INC?
What are today’s traded volumes of SIENTRA INC?
What is today’s market capitalisation of SIENTRA INC?
What is the 52 Week High and Low Range of SIENTRA INC?
How much percentage SIENTRA INC is down from its 52 Week High?
How much percentage SIENTRA INC is up from its 52 Week low?
What are the historical returns of SIENTRA INC?
Who is the Chief Executive Officer (CEO) of SIENTRA INC?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*